for the primary outcome (Table 2) . However, late enrollees experienced comparatively greater mortality benefit with exercise training than early enrollees. Our data demonstrate that patient characteristics and treatment adherence can change over the course of a large clinical outcomes trial. Utilization of evidencebased therapies for HF improved over time, suggesting that despite strict inclusion/exclusion criteria, the enrolled population reflected changes in management similar to those experienced by the general population Baseline characteristics by time of enrollment and randomization arm. Values are presented as n (%), or median (interquartile range). ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BUN, blood urea nitrogen; CCS, Canadian Cardiovascular Society; HF, heart failure; HR, heart rate; ICD, implantable cardioverter defibrillator; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MR, mitral regurgitation; and NYHA, New York Heart Association. during this time period. 4 However, baseline characteristics were largely similar between patient groups by randomization arm and time of enrollment. Late enrollees were also more adherent with the exercise intervention potentially because of increased focus on adherence by investigators and overall improvement in performance of study staff with time. All of these changes, including increased adherence in the late enrolled group, may have contributed to the mortality benefit observed with exercise in late enrollees, a benefit not noted in the overall trial. 2 These findings have important implications for trial design and interpretation. Based on our analysis of the ClinicalTrials.gov database, phase 3 to 4 cardiovascular trials completed between 1991 and 2016 (n=1282) lasted for 3.4 years on average, enrolling 964 subjects, compared with 4.9 years for HF-ACTION. Thus, with an average duration of 3 to 4 years, temporal changes in the state-of-the-art management of conditions such as cardiovascular disease may affect trial findings despite randomization and blinding. Although our findings are hypothesis generating and we cannot rule out residual confounding factors, they suggest that time of enrollment could be included in the variables used for covariate adjustment within the outcome analysis of long duration trials during which background therapy, clinical characteristics or adherence to therapy may change. These findings are important particularly given that many trials implement strategies and protocols that may be subject to variable implementation and adherence similar to the exercise intervention in HF-ACTION.
Our results point to the importance of timely enrollment and the importance of maintaining intervention adherence, both to avoid such confounding interactions and to render the overall findings more appropriately applicable to the contemporary population at the time of publication. However, given the exploratory nature of this analysis, additional analyses exploring this concept in other data sets would help support the potential implications of time of enrollment over the duration of a long-term outcome trial.
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